<DOC>
	<DOC>NCT02341625</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and gastric cancer.</brief_summary>
	<brief_title>A Study of BMS-986148 in Patients With Select Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Must have pancreatic, ovarian, gastric, nonsmall cell cancer or mesothelioma. For dose expansion, must have tumor that is positive for mesothelin Expected to have life expectancy of at least 3 months Men and women 18 years old or older (or local age of majority) Must have measurable tumor per Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST for malignant pleural mesothelioma ECOG of 0 to 1 Cancer metastases in the brain Moderate eye disorders Active infection or past hepatitis B or C infection Major surgery less than 1 month before the start of the study Uncontrolled heart disease Impaired liver or bone marrow function History of allergy to mesothelindirected antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>